Anavex Life Sciences Corp (AVXL)

[sokol]

CTAD presentation: The 15 minute presentation will be limited to cognitive measures from the PDD study that are relevant to Alzheimer's. We should not expect a full discussion of the PDD data - only the data that relates to Alzheimer's, which is relevant to this Alzheimer's conference. The final program schedule/agenda for CTAD 2020 that is available and may be downloaded from the site provided below. Anavex’s presentation on November 6 at 11:00 EST will be an analysis of “Cognitive Outcome Measures Relevant in AD” of the PDD phase 2 clinical trial. So, this will be about cognitive measures from the PDD trial and how those measures apply to Alzheimer’s Disease. Do NOT expect a full blown discussion of the PDD data, which, of course, is not relevant to this conference! And, do not be disappointed with the limitations placed on this presentation! https://www.ctad-alzheimer.com/files/files/DIGITALprogram_CTAD2020_23oct.pdf